Brokers Set Expectations for BDRX FY2028 Earnings

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) – Equities research analysts at Zacks Research issued their FY2028 earnings per share (EPS) estimates for shares of Biodexa Pharmaceuticals in a report released on Monday, June 29th. Zacks Research analyst D. Bautz expects that the company will post earnings of $0.00 per share for the year.

A number of other analysts also recently commented on the company. Weiss Ratings upgraded Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, June 18th. Wall Street Zen cut Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, March 30th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Biodexa Pharmaceuticals Stock Down 2.4%

NASDAQ BDRX opened at $2.85 on Tuesday. The business has a 50 day moving average price of $3.37 and a 200 day moving average price of $6.97. Biodexa Pharmaceuticals has a 1-year low of $2.45 and a 1-year high of $66.50.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last released its quarterly earnings results on Friday, March 27th. The company reported $3.52 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $3.53.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC bought a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned approximately 14.71% of Biodexa Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 17.51% of the company’s stock.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.